Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jul 15:14:27536351251340216.
doi: 10.1177/27536351251340216. eCollection 2025 Jan-Dec.

Cryoneurolysis: A Novel Treatment for Management of Spasticity. Presentation of a Case Series

Affiliations
Case Reports

Cryoneurolysis: A Novel Treatment for Management of Spasticity. Presentation of a Case Series

Anton Pick et al. Adv Rehabil Sci Pract. .

Abstract

Background: Spasticity is a motor phenomenon occurring in disorders of the central nervous system that impacts on active and passive function, and quality of life. Pharmacological, physical and surgical management options are available, each of which have limitations. Cryoneurolysis is a technique developed for the treatment of pain which involves the controlled freezing and thawing of peripheral nerves. Recent case reports and series have suggested it may offer a novel treatment approach for pain associated with spasticity.

Objectives: To report on the evaluation of cryoneurolysis in the first cohort of patients treated in a UK spasticity clinic.

Methods: Eight patients with a variety of neurological conditions (aged 25-75 years) underwent cryoneurolysis. Each had been receiving regular botulinum toxin injections and had ongoing treatment goals. All patients first underwent diagnostic nerve blocks with local anaesthetic to determine their appropriateness for the treatment. Cryoneurolysis was then performed with ultrasound and nerve stimulator guidance. Assessments included goal attainment, Modified Ashworth Scale (MAS), ArmA, LegA and the patient reported impact of spasticity scale (PRISM), alongside patient satisfaction and side effect questionnaires. Assessments were at baseline and at regular intervals over 9 to 12 months.

Results: All patients attained at least one of their goals, with sustained effect for more than 6 months. MAS demonstrated mixed or modest improvements. Functional outcome measures (ArmA/LegA) showed several meaningful improvements, particularly in passive function. There was an indication of an improvement in PRISM across domains, which plateaued at 6 months. Post-procedure pain was the most common side effect but subsided in all affected patients by 3 months. Patient satisfaction was positive.

Conclusions: Our findings contribute to a growing base of case reports and series suggesting that cryoneurolysis could be a potentially useful treatment modality for spasticity. Future controlled studies should aim to evaluate cost-effectiveness and compare with existing treatments.

Keywords: case reports; cryoneurolysis; goal attainment; neurological conditions; pain; spasticity.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: AP has received honoraria from Ipsen and Merz. RD and MKF have no competing interests to declare.

Figures

Figure 1.
Figure 1.
Top Panel: LegA score over time for individual patients, A = passive care, B = active function, C = quality of life. Bottom Panel: ArmA score over time for individual patients. D = passive care, E = active function. Lower numbers indicate better function or quality of life.
Figure 2.
Figure 2.
Median score across patients for each subcomponent of the PRISM. Lower values indicate less impact of spasticity.

Similar articles

References

    1. Sangari S, Perez MA. Prevalence of spasticity in humans with spinal cord injury with different injury severity. J Neurophysiol. 2022;128:470-479. doi: 10.1152/jn.00126.2022 - DOI - PMC - PubMed
    1. Zeng H, Chen J, Guo Y, Tan S. Prevalence and risk factors for spasticity after stroke: a systematic review and meta-analysis. Front Neurol. 2020;11:616097. doi: 10.3389/fneur.2020.616097 - DOI - PMC - PubMed
    1. Bethoux F, Marrie RA. A cross-sectional study of the impact of spasticity on daily activities in multiple sclerosis. Patient. 2016;9:537-546. doi: 10.1007/s40271-016-0173-0 - DOI - PubMed
    1. Milinis K, Young CA. Systematic review of the influence of spasticity on quality of life in adults with chronic neurological conditions. Disabil Rehabil. 2016;38:1431-41. doi: 10.3109/09638288.2015.1106592 - DOI - PubMed
    1. Jacinto J, Varriale P, Pain E, Lysandropoulos A, Esquenazi A. Patient perspectives on the therapeutic profile of botulinum neurotoxin type a in spasticity. Front Neurol. 2020;11:388. doi: 10.3389/fneur.2020.00388 - DOI - PMC - PubMed

Publication types

LinkOut - more resources